Latest Conference Articles

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.

J&J's Oncology Care Index finds a systems problem, not a confidence gap, in community oncology, Mahadi Baig, MD, says.

Bundled payment models offer employers and community oncology practices greater cost predictability while improving patient access, Baird said.

Jeff Hunnicutt emphasized vetting prior authorization vendors, scaling beyond single use cases, and AI's potential to streamline workflows.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Rosa Novo discusses tailoring cancer benefits to workforce needs, improving access and prevention, and return-to-work support.

Employers can advance patient-centered oncology care through proactive benefits, quality data, navigation, and tailored support, Amanda Green, MPH, said.

Experts at ERS Congress 2026 discuss why attending respiratory conferences drives learning, networking, and better patient outcomes.

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to wider uptake.

Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.

Lalan Wilfong, MD, discusses how model assumptions, cohort design, and risk adjustment shape performance and accountability in value-based oncology.

Francesca Polverino, MD, PhD, says COPD care still lacks a true precision medicine approach.

AI tools can ease administrative burden in community oncology, but practices face adoption, security, compliance, bias, and error concerns.

A Danish cohort study found 100% RSV vaccine effectiveness in COPD, but Jorgen Vestbo, MD, urges caution interpreting real-world results.

Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD, explained.

Laura Fabbri, MD, says patient wishes should guide care decisions in IPF and lung cancer overlap.

Francesca Polverino, MD, PhD, says COPD exacerbation severity lacks a clear definition, complicating GOLD's escalation criteria.

Jorgen Vestbo, MD, on the COPERNICOS trial results, long-term antibiotic use versus resistance concerns, and where COPD treatment is headed.

Francesca Puggioni, MD, discusses real-world exacerbations, biomarker-driven access, and barriers to earlier biologic use in asthma and COPD.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

Lung transplant candidates are aging rapidly, while cystic fibrosis decline in children shifts pediatric transplant toward sicker, more complex patients.

John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin deficiency.

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

Exposure prevention, primary care capacity, and digital health equity all shape the future of respiratory disease care.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.